Evaluation of Ebola Virus Inhibitors for Drug Repurposing

Peter B. Madrid, Rekha G. Panchal, Travis K. Warren, +9

ACS Infectious Diseases

Systematic ScreenEbola Virus InhibitorsAntibioticsMedicineAntiviral Drug Development +13

(+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of <i>Plasmodium</i>

Marı́a Belén Jiménez-Dı́az, Daniel Ebert, Yandira G. Salinas, +46

Proceedings of the National Academy of Sciences

Phenotypic ScreeningAntiparasitic AgentMalariaImmunologyMolecular Biology +15

Enhanced Anti-HIV Efficacy of Indinavir After Inclusion in CD4-Targeted Lipid Nanoparticles

Aaron N. Endsley, Rodney J. Y. Ho

JAIDS Journal of Acquired Immune Deficiency Syndromes

Design and Characterization of Novel Peptide-Coated Lipid Nanoparticles for Targeting Anti-HIV Drug to CD4 Expressing Cells

Aaron N. Endsley, Rodney J. Y. Ho

The AAPS Journal

NanoparticlesNanomedicineAnti-hiv DrugLipid PreparationEngineering +8

First in Human Evaluation and Dosimetry Calculations for Peptide 124I-p5+14—a Novel Radiotracer for the Detection of Systemic Amyloidosis Using PET/CT Imaging

Jonathan S. Wall, Emily B. Martin, Aaron N. Endsley, +10

Molecular Imaging and Biology

Positron Emission TomographyEngineeringMedical ImagingNovel RadiotracerPet-mri +7

Comparative analysis of the substrate preferences of two post‐proline cleaving endopeptidases, prolyl oligopeptidase and fibroblast activation protein α

Kalyani Jambunathan, Douglas S. Watson, Aaron N. Endsley, +2

FEBS Letters

Biodistribution of the Multidentate Hydroxypyridinonate Ligand [¹⁴C]‐3,4,3‐LI(1,2‐HOPO), a Potent Actinide Decorporation Agent

Taylor A. Choi, Aaron N. Endsley, Deborah I. Bunin, +8

Drug Development Research

β-Carotene Biosynthesis in Probiotic Bacteria

Jennifer Miller, Mike T. Harrison, Annalisa D’Andrea, +4

Probiotics and Antimicrobial Proteins

Biosynthesisβ-Carotene BiosynthesisEngineeringBiochemistryCarotenoid +2

FC 040INTERIM RESULTS OF PHASE 1 AND 2 TRIALS TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND CLINICAL ACTIVITY OF BION-1301 IN PATIENTS WITH IGA NEPHROPATHY

Jonathan Barratt, Billy Hour, Cailin Sibley, +6

Nephrology Dialysis Transplantation

Glomerular DiseaseRenal PathologyImmunologyRenal InflammationImmunotherapy +25

POS-109 INTERIM RESULTS OF PHASE 1 AND 2 TRIALS TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND CLINICAL ACTIVITY OF BION-1301 IN PATIENTS WITH IgA NEPHROPATHY

Jonathan Barratt, Billy Hour, Laura Kooienga, +9

Kidney International Reports